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Abstract
This study aimed to describe clinical outcomes in patients prescribed teriparatide and followed up for 18 months after 
stopping the drug in real-life conditions. The Extended Forsteo® Observational Study analysed incident clinical fractures 
in 6-month intervals using logistic regression with repeated measures. Changes in back pain (visual analogue scale) and 
health-related quality of life (HRQoL; EQ-5D questionnaire) were analysed using mixed models for repeated measures. 
Patients were analysed if they had a post-baseline visit, regardless of whether and for how long they took teriparatide. Of 1531 
patients analysed (90.7% female, mean age: 70.3 years), 76 (5.0%) never took teriparatide. Median treatment duration was 
23.6 months. The adjusted odds of clinical fracture decreased by 47% in the > 12- to 18-month treatment period (p = 0.013) 
compared with the first 6-month period, with no statistically significant reduction in the > 18- to 24-month interval. The 
clinical fracture rate remained stable during the 18 months’ post-teriparatide, when approximately 98% of patients took 
osteoporosis medication (51% bisphosphonates). Clinical vertebral fractures were reduced at every time period compared 
with the first 6 months. Adjusted mean back pain scores decreased and EQ-5D scores increased significantly at each post-
baseline observation. In a real-life clinical setting, the risk of clinical fractures declined during 24 months of teriparatide 
treatment. This reduction was maintained 18 months after stopping teriparatide. In parallel, patients reported significant 
improvements in back pain and HRQoL. The results should be interpreted in the context of the non-controlled design of 
this observational study.
Keywords Back pain · Fracture · Observational study · Osteoporosis · Quality of life · Teriparatide
Introduction
Teriparatide (recombinant human parathyroid hormone, For-
steo®) is an osteoanabolic agent that stimulates osteoblastic 
bone formation to improve bone quality and mass [1]. Teri-
paratide was first approved in Europe for up to 18 months’ 
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treatment of postmenopausal women with severe osteopo-
rosis. It subsequently received additional approval for the 
treatment of osteoporosis in men, and for the treatment of 
osteoporosis associated with glucocorticoid therapy in men 
and women at risk of fracture. More recently, the European 
Medicines Agency approved teriparatide treatment for up to 
24 months’ duration [2].
The reduction in risk of new fractures during teriparatide 
treatment in pivotal phase III randomised controlled trials 
(RCTs) [3–5] has been supported by data from prospective 
observational studies, including the European Forsteo® 
Observational Study (EFOS) [6, 7], the Direct Assess-
ment of Non-vertebral fractures in Community Experience 
(DANCE) study in the USA [8, 9] and a Japanese observa-
tional study [10], as well as registry studies [11–13].
The Extended Forsteo® Observational Study (ExFOS) 
was a non-interventional, prospective, single-cohort, obser-
vational study conducted in eight European countries [14] 
that addressed the need for a large real-life clinical practice 
study of teriparatide treatment after the update of the teri-
paratide European label, i.e. the extended treatment duration 
to 24 months, as well as the newly approved therapeutic 
indications in the context of osteoporosis treatment guide-
lines in the participant countries. Here we report the inci-
dence of clinical vertebral and non-vertebral fractures, as 
well as changes in back pain and health-related quality of 
life (HRQoL) over 42 months (i.e. up to 24 months of teri-
paratide treatment and 18 months of follow-up after stopping 
teriparatide).
Methods
Study Design and Patients
The study design and baseline characteristics of the patient 
population enrolled in ExFOS [14] and the results of the 
24-month teriparatide active treatment phase [15] have been 
reported previously. Briefly, ExFOS was conducted at 111 
centres in Croatia, Denmark, France, Greece, Italy, Nor-
way, Slovenia and Sweden. The first patient was enrolled 
on 24 May 2006 and the last patient completed the study 
on 3 February 2016. The study population consisted of 
men and women with osteoporosis who were judged suit-
able for teriparatide treatment by their physician. Patients 
were enrolled during routine clinical practice if they were 
teriparatide-naïve at enrolment. They were prescribed teri-
paratide (20 µg administered once daily by subcutaneous 
self-injection) at the baseline visit. Patients were excluded 
if they were currently being treated with an investigational 
drug or procedure, or if teriparatide was contraindicated 
according to the European label [2]. As this was an observa-
tional study collecting data in real-life conditions, there were 
no further restrictions for patient selection and patients were 
analysed regardless of whether and for how long they took 
the prescribed medication. Patients gave written informed 
consent prior to enrolment and could withdraw without con-
sequences at any time. The study was approved by local 
ethics committees or review boards, depending on local 
requirements.
The study consisted of two sequential phases: (1) an 
active treatment phase of up to 24 months, during which 
patients were treated with teriparatide (which could be dis-
continued at any time) and (2) a post-treatment follow-up 
phase after discontinuation of teriparatide. In France and 
Sweden, teriparatide was reimbursed for 18 months only; 
in the other six countries, teriparatide was reimbursed for 
24 months (in Denmark and Norway, the reimbursement 
period was extended from 18 to 24 months while the study 
was ongoing). During and after treatment with teriparatide, 
patients could be treated with any pharmacological inter-
vention prescribed by their physician for the treatment of 
osteoporosis.
Data Collection
All data collection and patient observations occurred within 
the normal course of clinical care. Data were collected at the 
baseline visit, at approximately 3, 6, 12, 18 and 24 months 
after starting teriparatide treatment, and at approximately 6, 
12 and 18 months after discontinuing teriparatide treatment. 
For the statistical analyses, actual patient visit dates were 
assigned to predefined time intervals given in the statistical 
analysis plan.
Patient information collected included demographic char-
acteristics, medical history, comorbidities and concomitant 
medications, lifestyle and risk factors for osteoporosis and 
falls, bone mineral density (BMD) (when available), osteo-
porotic fracture history (number, location and approximate 
date) and previous and current osteoporosis therapies. Phy-
sicians also recorded the date teriparatide treatment started 
and stopped. Patient persistence with teriparatide was 
assessed at each visit through self-report.
Fractures
The primary endpoint was the incidence of clinical fractures 
(a composite of clinical vertebral and non-vertebral frac-
tures). Patients were queried at each visit about the incidence 
of new clinical fractures; for all fractures, the locations and 
dates were recorded. A clinical vertebral fracture was identi-
fied from the presence of a confirmed radiographic vertebral 
fracture associated with signs or symptoms suggestive of a 
vertebral fracture [16], in accordance with the physicians’ 
clinical practice. Morphometric, asymptomatic vertebral 
fractures were neither collected nor included in the analyses. 
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Secondary fracture outcomes included non-vertebral fragil-
ity fractures and main non-vertebral fragility fractures (fore-
arm/wrist, hip, humerus, leg and ribs).
Back Pain
Back pain was self-assessed by patients at each visit using a 
questionnaire evaluating the frequency and severity of back 
pain as well as limitations of activities and days in bed due 
to back pain, all during the past month before the visit [6]. 
Patients also rated the severity of back pain using a visual 
analogue scale (VAS) ranging from 0 mm (no back pain) to 
100 mm (worst possible back pain), which has been shown 
to be a reliable measure of pain [17]. In addition, patients 
indicated the type and frequency of analgesic medication 
used for their back pain in the past month.
Health‑Related Quality of Life
HRQoL was self-assessed by patients at each visit using the 
EuroQoL-5 Dimension (EQ-5D) questionnaire [18]. Patients 
rated their current health state in five domains (mobility, 
self-care, usual activities, pain/discomfort and anxiety/
depression), scoring each domain on a 3-point scale. From 
the domain scores, a single Health State Value (EQ-5D 
HSV) was calculated based on the UK scoring algorithm 
[19]. Patients also rated their overall health status on the 
day of assessment using the EQ-5D VAS (EQ-VAS), which 
ranged from 0 (worst imaginable health state) to 100 (best 
imaginable health state).
Safety
Spontaneously reported adverse events were collected 
throughout the study.
Statistical Analysis
Data were analysed for the Total Study Cohort, which—
given the pragmatic design of the study—included patients 
with baseline data and at least one post-baseline visit with 
non-missing effectiveness data, regardless of whether and 
for how long they had taken teriparatide after its prescription 
(i.e. an intention-to-treat principle was applied). Two addi-
tional cohorts were predefined and analysed: (1) the Active 
Treatment Cohort, which included patients with baseline 
data and at least one visit at or before the end of teriparatide 
treatment with non-missing data; this excluded patients who 
did not take teriparatide [15]; (2) the Post-Treatment Follow-
Up Cohort, which included patients with baseline data who 
had received and then discontinued teriparatide, and had 
at least one post-teriparatide visit with non-missing data; 
results for this cohort are also reported here. All models used 
and analyses performed were prespecified in the statistical 
analysis plan.
Descriptive statistics (frequencies, percentages, means 
and standard deviations [SDs] or medians with interquartile 
ranges [Q1, Q3]) were used to describe the study population, 
persistence with teriparatide treatment and safety results. 
Incident fractures, back pain and HRQoL were summarised 
over 42 months. While patients could remain in the study 
beyond 42 months, most of the reported analyses were 
restricted to this period because of low patient numbers at 
later time points.
The number of patients with at least one clinical frac-
ture was summarised in 6-month intervals up to 42 months. 
Logistic regression analysis with repeated measures was 
used to assess the respective odds of fracture (i.e. the ratio 
of patients who had a fracture in an interval vs those who did 
not have a fracture in that interval). Patients were included 
in the model at all observed intervals, regardless of whether 
they had a fracture during the previous interval or were tak-
ing teriparatide. The repeated observations of each patient 
were assumed to be related but no further assumptions were 
made about the relationship. Contrasts were made between 
the odds of fracture in the first 6-month period (the reference 
interval) and each subsequent 6-month period. The results 
are presented as odds ratios (OR), 95% confidence intervals 
(95% CI) and p values. Fracture modelling was repeated for 
clinical vertebral fractures, all non-vertebral fractures and 
the main non-vertebral fractures.
A Cox proportional hazards model was used to evalu-
ate the association of the baseline covariates used in the 
adjusted logistic regression model with time to first on-study 
fracture. The results are presented as hazard ratios (HR) with 
associated 95% CIs.
Changes from baseline in back pain VAS, EQ-5D HSV 
and EQ-VAS scores were analysed for each visit using mixed 
models for repeated measures (MMRM), adjusting for pre-
selected variables. For each visit, the numbers of patients 
reporting an improvement, no change or worsening from 
baseline in back pain frequency, severity and limitations in 
activities during the month prior to the visit and in each 
EQ-5D domain were calculated and analysed using the Wil-
coxon signed-rank test.
Statistical analyses were conducted using SAS version 9.4 
(SAS Institute, Cary, USA).
Results
Patient Disposition and Characteristics
Of the 1611 patients enrolled in ExFOS, 1531 were ana-
lysed in the Total Study Cohort, including 76 subjects who 
had a teriparatide prescription but never took the drug. 
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Patient flow through the study and the number of patients 
at each visit for the Total Study Cohort are presented in 
Fig. 1. Within this cohort, 998 (65.2%) patients completed 
42 months of follow-up.
Baseline characteristics of the Total Study Cohort are 
summarised in Table 1. Mean (SD) age was 70.3 (9.8) 
years, the majority (90.7%) were female, 14.6% were taking 
glucocorticoids and 88.6% reported taking prior osteopo-
rosis medication. At baseline, 85.4% of patients reported 
at least one previous osteoporotic fracture and 66.2% had 
two or more previous osteoporotic fractures. Overall, 77.3% 
of patients had a previous vertebral fracture (54.6% had at 
least two previous vertebral fractures) and 42.2% had a pre-
vious non-vertebral fracture. The median (Q1, Q3) number 
of previous fractures was 2.0 (1.0, 4.0). A high proportion 
of patients reported having fractures in the 12 months before 
baseline: 47.6% had any type of fracture and 41.6% had a 
vertebral fracture (Table 1).
When the main baseline characteristics and risk factors 
of participants were summarised descriptively by gender, a 
higher proportion of men than women had previous fracture 
(91.6 vs. 84.8%), previous vertebral fracture (84.6 vs. 76.6%) 
and were taking glucocorticoids at baseline (21.7 vs. 13.9%), 
while fewer men had taken prior osteoporosis medication 
(76.2 vs. 89.9%).
Teriparatide Treatment (Active Treatment Cohort)
The median duration of treatment with teriparatide in the 
1454 analysed patients, excluding total treatment inter-
ruption (sum of treatment interruption in days from 
0‒24 months), was 719  days (23.6  months; Q1; Q3: 
18.1; 24.0 months; mean [SD]: 20.7 [5.2] months; range 
0–66 months). Treatment interruptions of more than 4 weeks 
at any time up to 24 months occurred in 67 patients (4.6%). 
The mean (SD) number of missed injections, calculated as 
the sum of reported missed injections during the last month 
before each visit, was 3.9 (8.9). Persistence with teriparatide 
treatment in the 18- and 24-month reimbursement countries 
is shown in Fig. 2: 88.6% of all evaluable patients were still 
taking teriparatide at 17 months.
3 months (N=1531)
Missed visit (N=229)
6 months (N=1531)
Missed visit (N=151)
12 months (N=1477)
Missed visit (N=124)
18 months (N=1423)
Missed visit (N=128)
24 months (N=1357)
Missed visit (N=191)
30 months (N=1268)
Missed visit (N=435)
36 months (N=1090)
Missed visit (N=526)
42 months (N=998)
Missed visit (N=253)
Total Study Cohort
Number of patients 
remaining in study
Baseline
(N=1531)
No more data (N=0)
No more data (N=54)
No more data (N=54)
No more data (N=66)
No more data (N=89)
No more data (N=178)
No more data (N=92)
Teriparatide
treatment 
for up to 24 
months
Teriparatide
discontinued
Post-Treatment Follow-Up 
Cohort
Discontinued teriparatide 
treatment
(N=1307)
6 months follow-up (N=893)
Missed visit (N=282)
18 months follow-up (N=939)
Missed visit (N=66)
No more data (N=132)
The number of patients from each participating country at baseline (Total Study Cohort) was: Greece: 434 (28.3%); Denmark: 309 (20.2%); 
Sweden: 287 (18.7%); Italy: 181 (11.8%); France: 166 (10.8%); Croatia: 63 (4.1%); Slovenia: 50 (3.3%) and Norway: 41 (2.7%). 
Fig. 1  Patient disposition through the study from baseline up to 42 months (Total Study Cohort and Post-Treatment Follow-up Cohort)
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The majority of patients took calcium (86%) and vitamin 
D supplementation (98%) during teriparatide treatment.
Fractures
Figure 3a shows the number and percentage of patients 
with at least one incident clinical fracture in each 6-month 
interval up to 42 months of follow-up in the Total Study 
Cohort. The ORs and 95% CIs show a 47% decrease in the 
adjusted odds of fracture in the > 12- to 18-month period 
(p = 0.013), a 51% decrease in the > 24- to 30-month period 
(p = 0.010) and a 73% decrease in the > 36- to 42-month 
period (p < 0.001) versus the first 6-month period. Note that 
the > 18- to 24-month period included a mix of subjects 
who were still taking teriparatide plus those who stopped 
the drug after 18 months mainly due to the different reim-
bursement status in the participant countries. The propor-
tions of patients with incident clinical vertebral fractures, 
Table 1  Patient baseline 
characteristics
Percentages are based on patients with non-missing data
a Includes all patients with a baseline visit and at least one post-baseline visit, with non-missing effective-
ness data
b Number of patients with corresponding BMD measurement at baseline
Characteristic Total Study  Cohorta
(N = 1531)
Female, n (%) 1388 (90.7)
Age, mean (SD) years 70.3 (9.8)
Body mass index, mean (SD) kg/m2 25.5 (4.5)
Patients with previous fracture, n (%) 1308 (85.4)
Patients with previous vertebral fracture, n (%) 1184 (77.3)
Number of previous fractures, median (Q1, Q3) 2.0 (1.0, 4.0)
Number of previous vertebral fractures, median (Q1, Q3) 2.0 (1.0, 3.0)
Patients with fractures in the 12 months before starting teriparatide, n (%) 729 (47.6)
Patients with vertebral fractures in the 12 months before starting teriparatide, n (%) 637 (41.6)
Maternal history of hip fracture, n (%) 248 (19.5)
BMD T-score, mean (SD)
 Lumbar spine (N = 1197)b − 3.03 (1.25)
 Total hip (N = 904)b − 2.44 (1.02)
 Femoral neck (N = 585)b − 2.51 (0.93)
Uses arms when standing from chair, n (%) 795 (52.2)
Sight problems, n (%) 492 (32.4)
Current smoker, n (%) 222 (14.7)
Exercises ≥ 1 h/week, n (%) 907 (60.1)
Has at least one alcoholic drink per week, n (%) 533 (35.6)
Number of patients with falls in previous year, n (%)
 1 Fall 302 (20.4)
 > 1 Fall 276 (18.7)
Immobilised for > 12 months, n (%) 48 (3.2)
Reproductive history for females (N = 1388)
 Reached menopause, n (%) 1044 (98.5)
 Years since onset of menopause, median (Q1, Q3) 23.0 (16.0, 30.0)
 Early menopause (< 40 years of age), n (%) 75 (5.9)
 Surgical menopause, n (%) 147 (11.1)
 Nulliparous, n (%) 152 (11.0)
Prior osteoporosis medication, n (%) 1357 (88.6)
Prior bisphosphonate use, n (%) 989 (64.6)
Duration of prior bisphosphonate therapy (months), mean (SD) 20.8 (37.2)
Current comorbidities, any disease, n (%) 519 (33.9)
Rheumatoid arthritis or other rheumatological disorder, n (%) 171 (11.3)
Taking glucocorticoids, n (%) 224 (14.6)
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non-vertebral fractures and main non-vertebral fractures 
in each 6-month period up to 42  months are shown in 
Fig. 3b–d, respectively. Compared with the first 6-month 
interval, there was a significant reduction in the adjusted 
odds of clinical vertebral fracture at all subsequent time 
points (Fig. 3b), but not for non-vertebral fractures. Details 
of the main non-vertebral fractures by location during the 
42 months are included in Online Resource 1.
Excluding the 76 patients who never started therapy with 
teriparatide from the analyses yielded similar fracture results 
(data not shown).
For the Total Study Cohort, the hazard of clinical frac-
ture was greater for patients with a history of vertebral and 
non-vertebral fracture in the 12 months before starting teri-
paratide versus those without such a history (Table 2). The 
other covariates in the Cox model (age, gender and prior 
bisphosphonate use) for time to first clinical fracture were 
not statistically significant.
Back Pain
The mean (SD) back pain VAS score at baseline was 50.2 
(27.0) mm. Figure 4 shows the decrease in the adjusted mean 
score in back pain VAS score (in mm) from baseline during 
up to 24 months of teriparatide treatment; this decrease was 
maintained during the 18 months after teriparatide discon-
tinuation. A sensitivity analysis using an extended adjusted 
MMRM model that included hours of physical activity at 
baseline, time since most recent vertebral fracture before 
baseline and use of analgesics as additional covariates, 
yielded similar results (see Online Resource 2). Further 
sensitivity analyses that excluded patients with rheumatoid 
arthritis also yielded similar results.
Results from the back-pain questionnaire, summarised in 
Online Resource 3, showed that the frequency and severity 
of back pain, limitations of activities and days in bed due to 
back pain in the past month decreased during teriparatide 
treatment for up to 24 months. This improvement was main-
tained after teriparatide treatment was discontinued.
The majority of patients reported using analgesic medi-
cation for back pain during the month before the baseline 
assessment (75%; 1104/1470); this number decreased to 
64% at 24 months and 63% at 42 months. Among patients 
who used analgesics, paracetamol was the most commonly 
used medication at all time points (77% at baseline, 74% at 
24 months, 84% at 42 months), followed by acetylsalicylic 
acid/non-steroidal anti-inflammatory drugs (34% at baseline, 
26% at 24 months, 23% at 42 months), low-potency opiates 
(25% at baseline, 21% at 24 months, 8% at 42 months) and 
high-potency opiates (11% at baseline, 7% at 24 months, 4% 
at 42 months).
Health‑Related Quality of Life
The mean (SD) EQ-VAS score at baseline was 56.5 (21.1), 
and the mean (SD) EQ-5D HSV at baseline was 0.50 (0.36). 
The adjusted mean changes in EQ-VAS score and EQ-5D 
HSV from baseline during and after teriparatide treatment 
(Fig. 5) showed statistically significant improvements at all 
post-baseline time points. The results were similar in the 
sensitivity analysis using an extended adjusted MMRM 
model for change from baseline in EQ-VAS score, which 
included the following additional covariates at baseline: 
hours of physical activity at baseline, time since most recent 
fracture (years) before baseline, back pain VAS at baseline, 
use of analgesics (yes/no) in the month prior to baseline and 
any comorbidities (see Online Resource 4).
Results for EQ-5D dimensions are summarised in 
Online Resources 5 and 6; changes over time showed that, 
at each post-baseline visit, there was a statistically signifi-
cant improvement compared to baseline. The proportion of 
patients showing improvement was greatest for the pain and 
discomfort domain (range 25.8% at 3 months to 53.4% at 
30 months) and the usual activities domain (range 27.8% at 
3 months to 47.5% at 42 months) (see Online Resource 6).
Post‑Teriparatide Cohort
Of the 939 patients in the Post-Treatment Follow-Up 
Cohort with data available, approximately 98% took any 
osteoporosis medication after teriparatide discontinuation, 
mainly bisphosphonates (51%). Potent antiresorptives (bis-
phosphonates, denosumab) were taken by approximately 
73% of the cohort. The drugs most commonly taken at 
least once after stopping teriparatide were denosumab 
(22%), alendronate and zoledronic acid (20% each). Most 
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Fig. 2  Persistence with teriparatide over time differentiated by 18- 
and 24-month reimbursement countries (data from Active Treatment 
Cohort). Countries with 24 months’ reimbursement for teriparatide 
(Croatia, Denmark, Greece, Italy, Norway, Slovenia) (n = 1038). Data 
missing for 41 patients. Countries with 18 months’ reimbursement for 
teriparatide (France, Sweden) (n = 417). Data missing for 51 patients
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patients continued with calcium (80%) and vitamin D sup-
plements (95%) after teriparatide was discontinued. For 
approximately 24% of the study cohort with data available, 
calcium and vitamin D was the only osteoporosis treat-
ment taken after teriparatide was discontinued. Details 
of clinical fractures during the 18 months after stopping 
teriparatide in the 1307 patients with data are given in 
Online Resource 7. The risk for new fractures of any cat-
egory remained very low (< 2% in all 6-month periods 
analysed), most notably for clinical vertebral fractures 
(0.2% of patients) and remained stable during the follow-
up period.
Safety
Adverse events experienced by patients in the active treat-
ment phase have already been reported [15]. Of the 1611 
enrolled patients, 173 (10.7%) had at least one adverse event 
and 120 (7.4%) had at least one serious adverse event dur-
ing the active treatment phase. Of the 339 adverse events 
reported in this period, 211 (62.2%) were serious and 57 
(16.8%) were considered possibly related to study medica-
tion. The most common adverse events (> 2%) were fall 
(7.1%), nausea (4.1%) and headache (2.9%). In the overall 
Total Study Cohort, which included the post-teriparatide 
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Fig. 3  Fracture outcomes in the Total Study Cohort during and after 
teriparatide treatment for a clinical fractures, b clinical vertebral 
fractures, c non-vertebral fractures and d main non-vertebral frac-
tures (forearm/wrist, hip, humerus, leg or ribs). To reflect real-life 
outcomes, 76 patients who never started treatment with teriparatide 
were also included in the analyses. *p < 0.1, **p < 0.05, ***p < 0.001; 
% and n above columns indicate percentage and number of patients 
at each time point with ≥ 1 fracture. For each patient with a fracture 
in the > 18- to 24-month interval, we determined whether the frac-
ture occurred while they were still taking teriparatide from the date of 
fracture and teriparatide stop date. Repeated measures logistic regres-
sion model adjusted for time point, age, sex, prior bisphosphonate use 
and a history of fracture in the 12 months before starting teriparatide; 
N number of patients with information on fractures in the time inter-
val, CI confidence interval, OR odds ratio
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treatment phase, there were a total of 363 adverse events 
(i.e. 24 more events than during the active treatment phase). 
No cases of osteosarcoma were observed during the full 
study duration. There were 38 patients with at least one 
adverse event leading to death (2.4% of all 1611 enrolled 
patients); none of these events leading to death were consid-
ered related to the study drug by the reporting investigators. 
In 4 cases, the cause of death was unknown or not reported. 
As expected in this elderly frail population, the main causes 
of death were malignancies of different origin (n = 7) and 
vascular acute events (cardiac and cerebral) (n = 6), followed 
by cardiac failure (n = 3) and sepsis (n = 3). Most of the 
reported deaths occurred during active teriparatide treatment 
or shortly after its withdrawal.
Discussion
The ExFOS study was designed to collect real-world data 
from European patients with severe osteoporosis in the usual 
clinical care setting who were prescribed teriparatide for the 
extended 24 months’ treatment duration and including the 
latest approved indications. Most of these patients had been 
widely exposed to prior osteoporosis therapies and included 
postmenopausal women, men and patients with glucocorti-
coid-induced osteoporosis. The study also included a post-
treatment follow-up observation period of at least 18 months 
to describe clinical outcomes after teriparatide treatment was 
discontinued and when patients were treated according to 
usual clinical care.
As our predefined analysis was based on an intention-
to-treat principle, the Total Study Cohort included a small 
proportion of patients (5%) who received a prescription for 
teriparatide but never took the drug. This differs from our 
previous analysis of the 24-month active treatment phase 
reported by Langdahl et al. [15], where the cohort analysed 
included only subjects who received at least one dose of teri-
paratide. Thus, the effectiveness analysis during teriparatide 
treatment in the current report includes non-compliant sub-
jects and, therefore, more closely reflects real-world clinical 
practice.
In the Total Study Cohort, the odds of clinical fracture 
(clinical vertebral plus non-vertebral) were significantly 
reduced by 47% in the > 12- to 18-month treatment period 
compared with the first 6 months of treatment, but were not 
significantly reduced in the > 18- to 24-month interval. One 
reason for this may be shorter than expected treatment expo-
sure to teriparatide in the > 18- to 24-month period due to 
lack of reimbursement of the drug after 18 months of treat-
ment in two participant countries (France, Sweden: 29.6% 
of the Total Study Cohort); this factor was not anticipated 
when the study was designed. As seen in Fig. 3a, about 
half of the patients with clinical fractures in the > 18- to 
24-month interval no longer took teriparatide. This prob-
ably explains the differential finding from the active treat-
ment phase reported by Langdahl et al. [15], where the odds 
of clinical fracture were significantly reduced by 49% (OR: 
0.51, 95% CI 0.29, 0.90; p < 0.05) in the > 18- to 24-month 
interval. Consistent with the cohort analysed by Langdahl 
et al. [15], however, we observed a significant reduction in 
the odds of sustaining a clinical vertebral fracture in the 
> 6- to 12-month, > 12- to 18-month and > 18- to 24-month 
intervals compared with the first 6-month interval in the 
Total Study Cohort (Fig. 3b).
Table 2  Cox proportional hazards analysis of time to first clinical 
fracture (Total Study Cohort)
CI confidence interval, HR hazard ratio
a Each additional year of age
Baseline variable Comparison HR (95% CI)
Gender Female versus male 1.96 (0.96, 4.01)
Age Unit = 1a 1.01 (0.99, 1.03)
Prior bisphosphonate use Yes versus no 1.35 (0.97, 1.88)
History of vertebral fracture 
in the last 12 months before 
starting teriparatide treat-
ment
Yes versus no 1.65 (1.23, 2.23)
History of non-vertebral frac-
ture in the last 12 months 
before starting teriparatide 
treatment
Yes versus no 1.82 (1.17, 2.82)
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Fig. 4  Change in back pain VAS score from baseline. Mixed model 
for repeated measures (MMRM) included change from baseline in 
back pain VAS score as a dependent variable, visit as a fixed repeated 
effect and baseline back pain VAS score, age, duration of prior bis-
phosphonate therapy, number of vertebral fractures at baseline, ver-
tebral fractures in the 12 months before starting teriparatide treatment 
and diagnosis of rheumatoid arthritis or other rheumatological disor-
der as covariates. The unadjusted mean (SD) back pain VAS scores at 
3, 6, 12, 18, 24, 30, 36 and 42 months were 41.1 (25.4), 35.6 (24.4), 
32.0 (23.9), 30.3 (24.1), 27.8 (24.4), 24.6 (23.5), 31.6 (25.0) and 22.3 
(22.2) mm, respectively. LS least squares, SD standard deviation, SE 
standard error, VAS visual analogue scale
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The reduction in risk of fracture during teriparatide treat-
ment is consistent with that seen during the observational 
EFOS study conducted in postmenopausal women with 
severe osteoporosis who were treated with teriparatide for up 
to 18 months and were followed up for 18 months after dis-
continuing teriparatide [20]. Our results extend these find-
ings over a longer treatment period and in a broader range 
of patients with osteoporosis: most patients in ExFOS were 
postmenopausal women, 9.3% were men and 14.6% were 
taking glucocorticoids at baseline.
Our findings also showed that the reduced risk of clinical 
fracture was maintained even after teriparatide had been dis-
continued and most patients had switched to another osteo-
porosis medication. Similarly, in EFOS, the odds of clinical 
fracture did not change in the 18-month post-teriparatide 
period, during which 63% of patients took bisphosphonates 
[7]. The benefits of previous teriparatide therapy were also 
shown in the follow-up study of the pivotal phase III Frac-
ture Prevention Trial (FPT), which analysed fractures sus-
tained by postmenopausal women with osteoporosis during 
an observational follow-up period after stopping teripara-
tide treatment [21]. During 18 months of follow-up, when 
47% of patients received osteoporosis medication (mostly 
bisphosphonates), the risk of new vertebral fractures was 
significantly reduced by 41% in women who had previously 
received teriparatide (20 µg/day) relative to the group who 
had previously received placebo [21].
In contrast to the present study, the DANCE observa-
tional study showed a significant reduction in non-vertebral 
fractures in men and women with osteoporosis treated with 
teriparatide for up to 24 months [8]. Compared with the first 
6-month period, the incidence of new non-vertebral fractures 
in DANCE was 36, 51 and 43% lower in the 6- to 12-month, 
12- to 18-month and 18- to 24-month periods, respectively 
(all p < 0.05) [8]. The differential results between ExFOS 
and DANCE for the non-vertebral fractures risk reduction 
may be explained by two important differences between the 
studies; in DANCE, only patients who received teriparatide 
were included in the analysis, and the sample size was sub-
stantially larger (3720 patients), which may have increased 
the statistical power to show a reduction in this type of frac-
ture compared to ExFOS.
Osteoporotic fractures are associated with pain, disabil-
ity and functional limitations that can adversely affect an 
individual’s quality of life [22–25]. A new vertebral frac-
ture can have long-lasting effects on quality of life for at 
least 12 months [26], which is why we adjusted for vertebral 
fractures in the 12 months before starting teriparatide in our 
analysis of back pain. In the present study, approximately 
half of the patients had a fracture (42% had a vertebral frac-
ture) in the 12 months before starting teriparatide, and 91% 
of patients reported having back pain at baseline, which was 
rated as moderate or severe in most cases. We observed a 
significant reduction in the severity of patient-reported back 
pain during up to 24 months of teriparatide treatment, which 
could also have been influenced by the natural history of 
pain evolution after a clinical vertebral fracture. Indeed, a 
post hoc analysis of back pain VAS results by time since 
last clinical vertebral fracture (data not presented) showed 
that the baseline mean back pain VAS score was higher in 
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Fig. 5  HRQoL changes from baseline for a EQ-VAS score and 
b EQ-5D HSV. Mixed models for repeated measures (MMRM) 
included change from baseline in EQ-VAS score or EQ-5D HSV 
as a dependent variable, visit as a fixed repeated effect and base-
line EQ-VAS score or EQ-5D HSV, age, duration of prior bisphos-
phonate therapy, number of fractures at baseline (total), fractures in 
the 12  months before starting teriparatide treatment and diagnosis 
of rheumatoid arthritis or other rheumatological disorder as covari-
ates. The unadjusted mean (SD) EQ-VAS scores at 3, 6, 12, 18, 24, 
30, 36 and 42 months were 61.8 (19.6), 64.8 (19.9), 67.4 (19.6), 68.9 
(19.5), 70.1 (20.3), 74.8 (19.3), 67.2 (19.2) and 76.0 (18.5), respec-
tively. The unadjusted mean EQ-5D HSV scores at 3, 6, 12, 18, 24, 
30, 36 and 42 months were 0.63 (0.31), 0.68 (0.27), 0.69 (0.28), 0.72 
(0.26), 0.73 (0.27), 0.78 (0.24), 0.68 (0.26) and 0.78 (0.24), respec-
tively. LS least squares, SD standard deviation, SE standard error, EQ-
VAS EuroQol-5 dimension visual analogue scale, EQ-5D EuroQol-5 
dimension, HSV health state value
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patients with a more recent clinical vertebral fracture (within 
the last month: 71.1 mm, SD 18.8 mm) than in patients with 
a clinical vertebral fracture that occurred more than 1 year 
previously (47.8 mm, SD 26.2 mm). Mean change from 
baseline back pain VAS score also demonstrated a relation-
ship with the time since the most recent vertebral fracture, 
with larger decreases in back pain VAS scores in the groups 
with more recent vertebral fractures.
Although the reduced incidence of new or worsening 
back pain in teriparatide-treated patients in earlier studies 
and meta-analyses may have been associated with a reduc-
tion in vertebral fractures [27–29], we do not believe this 
is the reason for our back-pain results in ExFOS, given the 
very low number of patients with incident clinical vertebral 
fractures during the course of the study. A similar reduction 
in back pain VAS scores was seen during 18 months of teri-
paratide treatment in the EFOS study [7]. Likewise, in the 
EUROFORS study of postmenopausal women with osteo-
porosis, teriparatide treatment for 24 months was associated 
with a significant reduction in back pain [30]. The meta-
analysis by Nevitt et al. [29] showed that the reduced risk 
of developing back pain in teriparatide-treated patients was 
sustained during 30 months of post-treatment observational 
follow-up, when 55% of patients received other osteoporosis 
medication. In ExFOS, we observed a reduction in patient-
reported use of strong analgesics (opiates). This is important 
for patients as it reduces the risk of falls and common side 
effects, such as nausea, constipation and drowsiness [31, 32].
Consistent with the results on back pain, patients reported 
a progressive improvement in HRQoL during teriparatide 
treatment for up to 24  months that was maintained for 
18 months after treatment was stopped. Similar HRQoL 
changes were seen in the EFOS study [33]. Although we 
observed improvements from baseline in all five domains 
of the EQ-5D, the largest improvements occurred in the 
domains of pain and discomfort and usual activities.
Better long-term persistence with teriparatide has been 
associated with a lower incidence of fractures [1, 12, 34, 35]. 
In the current study, although teriparatide was administered 
by daily injection, persistence was good: 89% of all patients 
were still taking teriparatide at month 17, while the rate of 
persistence was 85% at 17 months and 74% at 23 months for 
countries with an 18- and 24-month reimbursement period, 
respectively. Moreover, < 5% of patients had treatment gaps 
of more than 4 weeks during teriparatide treatment.
Most patients (89%) had taken osteoporosis medication 
before starting teriparatide and 98% took osteoporosis medi-
cation after stopping teriparatide. Bisphosphonates were the 
most commonly used medication, although denosumab was 
taken by 22% of patients after stopping teriparatide. Because 
the approved duration of teriparatide treatment is limited to 
24 months, subsequent therapy is important to maintain the 
gains in bone density made with teriparatide [36]. In the FPT 
follow-up study, discontinuation of teriparatide resulted in 
a progressive, slow decrease in total hip and femoral neck 
BMD among patients who took no osteoporosis drug therapy 
after stopping teriparatide, with BMD values returning to 
pre-treatment levels approximately 30 months after stopping 
treatment [37]. However, the optimal sequential therapy after 
discontinuation of teriparatide remains unclear, and stud-
ies in this area have not been powered to measure fracture 
outcomes but rather use surrogate markers, such as BMD 
and biochemical markers of bone turnover [38, 39]. Existing 
evidence supports the use of antiresorptive agents (including 
bisphosphonates, raloxifene and denosumab) after stopping 
teriparatide, since use of such drugs can maintain or further 
increase BMD after teriparatide discontinuation [37–42]. 
However, fracture outcomes based on properly designed 
studies of sequential therapy are still lacking.
The real-life results of the ExFOS study are supportive 
for the role of bone anabolic agents as first-line therapy in 
patients with severe osteoporosis and prevalent fractures, 
followed by antiresorptives whenever possible. This therapy 
sequence is also supported by early reports with teripara-
tide [37] as well as recent phase III clinical trials of short-
term treatment with osteoanabolic agents, such as abalo-
paratide [43] and romosozumab [44], followed by potent 
antiresorptives.
The ExFOS study has several potential limitations, the 
main one being the lack of a non-teriparatide control group. 
Therefore, we used the first 6-month treatment period as 
the reference interval for calculating the ORs for fracture, 
because Kaplan–Meier analysis of non-vertebral fractures 
in the FPT showed that fracture incidence in the teripara-
tide and placebo groups began to separate after approxi-
mately 9 months of treatment [3]. Although we controlled 
for prior fracture in the statistical analyses, there may have 
been some regression to the mean over time, irrespective of 
treatment. Second, the relatively small number of patients 
with incident fractures resulted in limited statistical power 
to detect follow-up differences in non-vertebral fractures 
compared to the first 6-month reference interval. Likewise, 
there were too few patients with incident fractures for sub-
group analyses, including comparison of fracture rates in 
patients with and without prior bisphosphonate use at base-
line. However, recent subgroup analyses of the fracture data 
from postmenopausal women with severe osteoporosis in 
the VERtebral fracture treatment comparisons in Osteo-
porotic women (VERO) randomised clinical trial showed 
that the antifracture efficacy of teriparatide, compared with 
risedronate, did not differ significantly between patients 
with prior bisphosphate use vs treatment-naïve patients or 
between patients with and without recent bisphosphonate 
use [45]. Similarly, the VERO trial found no effect on overall 
efficacy results of prior recent clinical vertebral fracture, or 
number and severity of prior vertebral fractures [45]. Third, 
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the shorter duration of teriparatide treatment in France and 
Sweden due to reimbursement criteria impacted the analysis 
of 18- to 24-month fracture results. Fourth, persistence with 
teriparatide was assessed by patient self-report (which may 
be subject to recall bias) and was not measured quantita-
tively. Thus, it cannot be ruled out that variability in treat-
ment persistence between patients had an impact on fracture 
risk analyses, especially considering that we also included 
in the analysis 5% of patients who never took teriparatide. 
Finally, there may be a risk of bias due to the preferential 
drop out of more severely affected patients.
Our study has several strengths. The observational study 
design permitted inclusion of a broad range of patients 
with severe osteoporosis (in accordance with the approved 
European label) and their assessment in a real-world clini-
cal setting. As the study included long-term follow-up after 
teriparatide was stopped and patients were switched to other 
osteoporosis therapies, it reflects real-life clinical practice, 
making the results applicable to the general osteoporosis 
population in Europe. In addition, our predefined analyses 
adjusted for variables that could potentially influence the 
fracture, back pain and HRQoL results, thereby underscor-
ing the robustness of the results.
Conclusions
In this observational study of postmenopausal women, 
men and patients with glucocorticoid-induced osteoporo-
sis, patients treated with teriparatide for up to 24 months 
in routine clinical practice showed a reduction in the inci-
dence of clinical fractures, notably vertebral fractures, which 
was maintained for at least 18 months after teriparatide was 
discontinued. This was accompanied by reductions in back 
pain and analgesic use, and improvement in HRQoL, which 
were also maintained after treatment discontinuation. Our 
observations support the use of teriparatide for the treatment 
of patients with osteoporosis at high risk of fracture for the 
full-approved treatment duration, followed by antiresorptive 
drugs. However, our results should be interpreted conserva-
tively in the context of the design of an observational study.
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